

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number
WO 02/072073 A2

(51) International Patent Classification⁷: **A61K 9/16**,
9/20, 31/40, A61P 3/06

(21) International Application Number: PCT/IB02/00736

(22) International Filing Date: 13 March 2002 (13.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
P-200100069 14 March 2001 (14.03.2001) SI

(71) Applicant (*for all designated States except US*): **LEK
PHARMACEUTICAL AND CHEMICAL COMPANY**
D.D. [SI/SI]; Legal Affairs and Industrial Property,
Verovskova 57, 1526 Ljubljana (SI).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **KERC, Janez**
[SI/SI]; Trebinjska 7, 1000 Ljubljana (SI). **MATEJA,**
Salobir [SI/SI]; ul. 28. Maja 9, 1000 Ljubljana (SI).
BAVEC, Sasa [SI/SI]; Mekinceva 15, 1000 Ljubljana (SI).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 02/072073 A2

(54) Title: ATORVASTATIN CALCIUM IN A PHARMACEUTICAL FORM, COMPOSITION THEREOF, AND PHARMACEU-
TICAL FORMULATION COMPRISING ATORVASTATIN CALCIUM

(57) Abstract: Atorvastatin calcium, the substance known by the chemical name (R-(R*,R*))-(2-(4-fluorophenyl)- β , δ -dihy-
droxy-5-(1-methylethyl)-3-phenyl-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid hemi calcium salt is known as HMG-CoA
reductase inhibitor and is used as an antihypercholesterolemic agent. Atorvastatin in the pharmaceutical compositions available in
the market, is usually prepared as its calcium salt since it enables atorvastatin to be conveniently formulated in the pharmaceutical
formulations, for example, in tablets, capsules, powders and the like for oral administration. Atorvastatin calcium can exist in an
amorphous form or in one of the at least four known crystalline forms (Form I, Form II, Form III and Form IV). Atorvastatin
calcium is the substance which is sparingly soluble in water, with pKa 4,5, and it has been found that the crystalline forms are less
soluble than the amorphous form, which may cause problems in bioavailability of atorvastatin in the body. The present invention
solves the problem of providing therapeutic equivalence of atorvastatin pharmaceutical formulation regardless the form (crystalline,
amorphous, mixture of both) of atorvastatin calcium used for its preparation.

EXPRESS MAIL NO. EV545395338US
DOCKET NO. PC25264A

**Atorvastatin Calcium in a Pharmaceutical Form, Composition thereof,
and Pharmaceutical Formulation comprising Atorvastatin Calcium**

The present invention relates to atorvastatin calcium in a
5 novel pharmaceutical form, a novel composition comprising
atorvastatin calcium, and a pharmaceutical formulation
comprising said atorvastatin calcium or said composition of
atorvastatin calcium. Furthermore, the present invention
relates to a process for the preparation of said pharmaceutical
10 formulation and the use of said pharmaceutical formulation
comprising atorvastatin calcium as active ingredient for the
treatment of hypercholesterolemia, hyperlipidemia and the like.

Atorvastatin calcium, the substance known by the chemical
name (R-(R*,R*)) -2-(4-fluorophenyl)- β , δ -dihydroxy-5-(1-methylethyl)-
15 3-phenyl-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid hemi
calcium salt is known as HMG-CoA reductase inhibitor and is
used as an antihypercholesterolemic agent. Processes for the
preparation of atorvastatin and key intermediates are disclosed
in the United States Patent Numbers: 5,003,080; 5,097,045;
20 5,103,024; 5,124,482; 5,149,837; 5,155,251; 5,216,174;
5,245,047; 5,248,793; 5,280,126; 5,342,952 and 5,397,792.
Atorvastatin in the pharmaceutical compositions available in
the market, is usually prepared as its calcium salt since it
enables atorvastatin to be conveniently formulated in the
25 pharmaceutical formulations, for examples, in tablets,
capsules, powders and the like for oral administration.

Atorvastatin calcium can exist in an amorphous form or in
one of the at least four known crystalline forms (Form I, Form
II, Form III and Form IV), which are disclosed in the patent
30 applications WO 97/3958 and WO 97/3959. It is known that the
amorphous forms of many pharmaceutical substances exhibit
different dissolution characteristics and bioavailability
patterns compared to the crystalline forms (Konno T., *Chem.
Pharm. Bull.*, 1990;38;2003-2007). Bioavailability is one of the

key parameters for many therapeutic indications and is dependent on the form of the substance to be used in the pharmaceutical formulation. Processes for the crystallization and the preparation, respectively, of the amorphous substance
5 are sometimes difficult to be performed, and as a product afford amorphous-crystalline mixtures with a changeable ratio of both forms, that is, crystalline form instead of amorphous form and vice versa. Since there are differences in the solubility among individual atorvastatin forms, as the patent
10 application WO 97/3960 particularly emphasizes, also having an indirect impact on its bioavailability, it is very important to ensure uniformity of the substance being employed in a pharmaceutical formulation. Further, in the experiment it was observed that in acidic environment all atorvastatin calcium
15 incorporated in a pharmaceutical formulation could not be dissolved because of the poor solubility of atorvastatin calcium and preparing a pharmaceutical formulation being constantly therapeutically equivalent was rendered impossible.

The problem of uniformity of atorvastatin calcium may be
20 solved by employing the processes in its finalization which provide constant physical characteristics of the product. The problem occurs when atorvastatin calcium of mutually variable physical characteristics from several different sources is used for the preparation of a pharmaceutical formulation. Optionally
25 the problem can be solved by preparing atorvastatin calcium as a crystalline form only (WO 97/3958 and WO 97/3959) and an amorphous form only (WO 97/3960, WO 01/42209, and Slovene patent application P-9900271), respectively, before it is incorporated in the formulation, which requires the use of an
30 additional operation resulting in 5 to 10% loss. Since the patient should be provided with the drug being constantly therapeutically equivalent regardless to the form of atorvastatin calcium (regarding physical characteristics) incorporated in a pharmaceutical formulation, we have decided
35 to solve the problem of the solubility of different forms of

atorvastatin calcium and consecutively its bioavailability at the level of the formulation. A further argument for this decision is the fact that atorvastatin calcium is an extremely expensive substance and all additional operations whereat a
5 loss of the substance is possible considerably reduce the economical production process.

The patent literature describes atorvastatin calcium as an unstable substance and offers numerous solutions to provide a stable atorvastatin pharmaceutical formulation. Thus, for
10 example, the stability of the formulation can be provided by the addition of a basic or a buffering agent to the formulation (WO 00/35425, WO 94/16603), namely by stabilizing the substance according to an analogous method described for pravastatin sodium in the patent application WO 01/93860. In order to
15 prepare a stabilized amorphous substance, a combination of the methods disclosed in WO 01/93860, Slovene patent application P-9900271, and WO 01/42209 can be used. Insofar none of the described solutions on atorvastatin pharmaceutical compositions and formulations solves the problem of uniformity of
20 atorvastatin calcium regarding the physical parameters (crystalline and amorphous form, respectively) and associated difficulties in providing therapeutic equivalence of atorvastatin calcium pharmaceutical formulation.

An object of the present invention is to solve the problem
25 of providing therapeutic equivalence of atorvastatin calcium in a pharmaceutical form or comprised in a composition or a pharmaceutical formulation regardless the form (crystalline, amorphous, mixture of both) of atorvastatin calcium being used for the preparation thereof. The object of the present
30 invention also relates to a pharmaceutical formulation containing an alkalisng or a buffering substance which improves the bioavailability of atorvastatin by increasing its solubility and dissolution rate in aqueous solutions.

These and further objects are accomplished by the present invention as defined in the claims.

In a first aspect of the present invention the object may be accomplished by atorvastatin calcium in a pharmaceutical
5 form having a pH equal to or greater than the pK_a+1 of atorvastatin calcium.

Moreover, in a second aspect of the present invention the object may also be accomplished by a composition comprising atorvastatin calcium providing a pH equal to or greater than
10 the the pK_a+1 of atorvastatin calcium to an aqueous solution thereof.

Furthermore, according to a third aspect of the present invention the above object may further be accomplished by a pharmaceutical formulation comprising atorvastatin calcium as
15 active ingredient, wherein the pharmaceutical formulation when dissolved in a liquid aqueous medium increases the pH of said medium to a pH equal to or greater than the pK_a+1 of atorvastatin calcium.

Further objects of the present invention can be achieved
20 by preferred embodiments as set forth in the dependent claims.

The features of the present invention will become more apparent from the following description of the preferred embodiments.

The inventors surprisingly found that atorvastatin calcium
25 in a pharmaceutical form according to the present invention or a composition comprising atorvastatin capable of providing a pH equal to or greater than the pK_a+1 of atorvastatin calcium to an aqueous solution improves the solubility of atorvastatin calcium dissolved therein such that it is negligible whether
30 the amorphous or the crystalline form is dissolved.

More specifically, in the experiments the applicant has found that the solubility of atorvastatin calcium in aqueous

solutions is markedly improved at pH values equal to or greater than pK_a+1 whereas surprisingly differences between atorvastatin calcium in crystal or amorphous form appear to be negligible. The pK_a of atorvastatin's terminal carboxyl group is 4.5. Based on the above, it is preferred that when pH in the gastric microenvironment equal to or greater than pK_a+1 , more preferably pH of 6, is provided resulting from the composition or the pharmaceutical formulation according to the present invention comprising atorvastatin calcium, differences in the solubility will no longer be noticeable between different forms of atorvastatin calcium with different physical characteristics. The atorvastatin calcium forms having different physical characteristics which may be present in the composition or the pharmaceutical formulation according to the present invention can either be the amorphous form, the crystalline form or both forms simultaneously. Moreover, the present invention is not limited to these forms, but any physical form of atorvastatin calcium can be present in the composition or the pharmaceutical formulation of the present invention. More preferably, the amorphous atorvastatin calcium may be present in a form having a large specific surface, in particular as micronized amorphous atorvastatin calcium. Atorvastatin having a large specific surface has a further improved solubility characteristic.

In order to adjust the pH of the aqueous solution in the appropriate range, the composition or the pharmaceutical formulation according to the present invention optionally comprises a pH adjusting substance. The adjusting substance suitably used in the present invention is not specifically limited, however a substance selected from the group consisting of metal oxides, inorganic bases, organic bases, and salts of organic and inorganic acids is preferable. More preferably used pH adjusting substances are selected of the group consisting of oxides or hydroxides of alkaline or alkaline earth metals, in particular MgO , alkaline phosphate buffers, in particular

Na_3PO_4 and Na_2HPO_4 , and organic amines, in particular tris(hydroxymethyl)methylamine.

In the present invention, the pharmaceutical formulation when used for a single administration and comprising atorvastatin calcium as active ingredient preferably comprises the pH adjusting substance in an amount of 0.2 to 2.0 mmol, and more preferably of 0.4 to 1.2 mmol. If the pH adjusting substance is comprised in the above specific range, the pH value of 900 ml aqueous HCl solution, more generally the pH value of an simulated gastric environment of the stomach, may be properly adjusted by single administration of the pharmaceutical formulation according to the present invention. Thus, an improved solubility characteristic of the atorvastatin calcium contained in the pharmaceutical formulation can be achieved, irrespective whether the atorvastatin calcium is contained in the amorphous and/or crystalline form.

Experiments

For *in vitro* simulation of preferred embodiments of atorvastatin calcium pharmaceutical formulations in acidic gastric environment of the stomach according to the present invention, the dissolution testing in a simulated gastric fluid having a pH value of about pH 3, and more specifically in 900 ml of aqueous 0.001M HCl solution, was performed. The concentration of dissolved atorvastatin was then measured at 10-minute intervals.

Four different formulations were prepared in form of tablets (A1, A2, A3 and A4; their composition is shown in Table 1), which were capable of providing different pH of the aqueous solution (obtained pH values of the solutions are shown in Table 2). Measurement results of the amount of dissolved atorvastatin in % are shown in Table 3.

Table 1

Composition	A1	A2	A3	A4
Atorvastatin amorphous, micronized*	20.00	20.00	20.00	20.00
Microcrystalline cellulose (Avicel PH112 or PH102)*	98.60	78.60	72.60	37.10
Lactose monohydrate (70-100 mesh)	34.80	34.80	34.80	20.00
Cross-linked carboxymethylcellulose (Ac-di-sol)	9.60	9.60	9.60	9.60
Polysorbate 80	1.30	1.30	1.30	1.30
Hydroxypropyl cellulose (Klucel EF)	2.00	2.00	2.00	2.00
MgO	-	20.00	26.00	-
Na ₂ HPO ₄	-	-	-	140.00
Microcrystalline cellulose (Avicel PH112)	71.90	71.90	71.90	48.20
Cross-linked carboxymethylcellulose (Ac-di-sol)	9.60	9.60	9.60	19.60
Aerosil 200	1.20	1.20	1.20	1.20
Mg stearate	1.00	1.00	1.00	1.00
TOTAL	250.00	250.00	250.00	300.00
Demi water for granulation	100.00	70.00	70.00	-
Ethanol refined (96%)	-	-	-	50.00

*- Atorvastatin in the form of calcium salt in an equivalent amount, the difference is adjusted with an amount of microcrystalline cellulose

- 5 All quantities required for the preparation of one tablet are given in milligrams.

Table 2

	A1	A2	A3	A4
pH (1 tablet in 900 ml aqueous 0.001M HCl solution) after 15 min	3.22	4.28	6.09	6.06
pH (1 tablet in 900 ml aqueous 0.001M HCl solution) after 30 min	3.21	4.67	8.88	6.02

Table 3

	A1	A2	A3	A4
10 min	56.5	69.7	74.9	62.2
20 min	66.1	80.1	91.1	99.0
30 min	70.6	85.8	96.3	97.9
40 min	74.4	87.0	98.2	98.3
60 min	75.6	89.6	99.8	98.8

- 10 As evident from the measurements, all atorvastatin was dissolved advantageously in the case if the tablet was capable to increase the pH to a value that meets atorvastatin calcium's pKa+1, more specifically the pH of 900 ml of an aqueous 0.001M

HCl solution for three pH units, that is at least to pH 6. In these cases atorvastatin was dissolved at much faster rates.

In addition to improvement of the solubility, pKa+1 surprisingly also leveled the difference in solubility between atorvastatin calcium in a crystalline form and an amorphous form. To prove the above statement the granulations with the additions of different alkalising or buffering agents and different physical forms of atorvastatin calcium were prepared. Comparison of the release rate of atorvastatin from the granulations with added alkalising or buffering agents to the release rate of atorvastatin from the reference granulations with no added alkalising or buffering substances was carried out (Table 4). The pH values of solutions provided by different granulations are shown in Table 5. Measurement results of the amount of dissolved atorvastatin in % at different time intervals are shown in Table 6.

Table 4

Composition	AK1	AK2	AK3	AA1	AA2	AA3
Atorvastatin crystalline*	20.0	20.0	20.0	-	-	-
Atorvastatin amorphous*	-	-	-	20.0	20.0	20.0
Microcrystalline cellulose (PH102)*	71.3	71.3	71.3	71.3	71.3	71.3
Lactose monohydrate (70-100 mesh)	34.8	34.8	34.8	34.8	34.8	34.8
Cross-linked carboxymethylcellulose (Ac-di-sol)	9.6	9.6	9.6	9.6	9.6	9.6
Polysorbate 80	2.6	2.6	2.6	2.6	2.6	2.6
Hydroxypropyl cellulose (Klucel EF)	2.0	2.0	2.0	2.0	2.0	2.0
Tris	110.0	-	-	110.0	-	-
Na ₃ PO ₄	-	80.0	-	-	80.0	-
Microcrystalline cellulose (Avicel PH112)	67.9	67.9	67.9	67.9	67.9	67.9
Cross-linked carboxymethylcellulose (Ac-di-sol)	9.6	9.6	9.6	9.6	9.6	9.6
Aerosil 200	1.2	1.2	1.2	1.2	1.2	1.2
Mg stearate	1.0	1.0	1.0	1.0	1.0	1.0
Demi water for granulation	80.0	80.0	80.0	80.0	80.0	80.0

*- Atorvastatin in the form of Ca salt in an equivalent amount, the difference is adjusted with an amount microcrystalline cellulose

All quantities required for filling one capsule are given in milligrams.

Table 5

	AK1	AK2	AK3	AA1	AA2	AA3
pH (1 capsule in 900 ml aqueous 0.001M HCl solution) after 15 min	6.68	6.28	3.14	5.81	6.28	3.20
pH (1 capsule in 900 ml aqueous 0.001M HCl solution) after 30 min	6.95	6.72	3.15	5.68	6.30	3.24

Table 6

	AK1	AK2	AK3	AA1	AA2	AA3
10 min	64.6	49.9	31.8	75.9	50.8	38.7
20 min	76.4	63.4	44.5	82.6	62.1	53.4
30 min	81.0	72.3	51.4	83.6	68.5	61.5
40 min	84.2	77.3	55.8	83.9	72.8	66.6

From the obtained results it is evident that the percentage difference in the amount of dissolved amorphous and crystalline atorvastatin calcium was approximately 20% when the granulation without added alkalising or buffering substance was used, and a difference appeared minimal (< 5%) when a buffering substance was added.

It was tried to additionally improve the solubility of amorphous atorvastatin calcium by enlarging the specific surface area of particles of the amorphous substance. Six different granulations were prepared in the same manner as in the previous experiment, the only difference being instead of crystalline atorvastatin, micronized amorphous atorvastatin calcium (AAM1, AAM2 and AAM3 samples) was used having several times larger specific surface area of the particles compared to nonmicronized. The pH values provided by the granulations are shown in Table 7. Measurement results of the amount of dissolved atorvastatin in % at different time intervals are shown in Table 8.

Table 7

	AAM1	AAM2	AAM3	AA1	AA2	AA3
pH (1 tablet in 900 ml aqueous 0.001M HCl solution) after 15 min	6.80	6.40	3.12	5.81	6.28	3.20
pH (1 tablet in 900 ml aqueous 0.001M HCl solution) after 30 min	6.76	6.44	3.30	5.68	6.30	3.24

Table 8

	AAM1	AAM2	AAM3	AA1	AA2	AA3
10 min	85.9	93.9	41.5	75.9	50.8	38.7
20 min	95.8	94.2	55.9	82.6	62.1	53.4
30 min	98.4	93.9	63.8	83.6	68.5	61.5
40 min	99.3	94.0	68.9	83.9	72.8	66.6

From the obtained results it is evident that there was practically no difference in the amount of dissolved amorphous and amorphous micronized atorvastatin when the granulation without added buffering agent was used, and the difference increased to more than 15 - 20 % when a buffering agent was added.

The aforementioned experiments surprisingly showed that it was possible to provide therapeutic equivalence of atorvastatin calcium in a pharmaceutical form, a composition thereof as well as pharmaceutical formulations regardless which form (crystalline, amorphous, mixture of both) of atorvastatin calcium was used for their preparation. Of paramount importance for providing the therapeutic equivalence is the capability of the atorvastatin calcium, the composition thereof, and the pharmaceutical formulation according to the present invention to provide a pH equal to or greater than the pK_a+1 of atorvastatin calcium to an aqueous solution. In a preferred embodiment atorvastatin calcium, the compositions and the formulation of the present invention have the capability to increase the pH of 900 ml aqueous 0.001M HCl solution to pH values equal to or greater than pK_a+1 or more, in particular pH 6 or more.

The other surprising finding was that the dissolved amount of micronized amorphous atorvastatin calcium in the granulation with added alkalising or buffering substance is approximately for 15% greater than in case of nonmicronized atorvastatin calcium. Here the most surprising fact is that an increase of a specific surface of the particles itself does not have an impact on the improvement of the solubility, as the solubility

of micronized and nonmicronized amorphous atorvastatin calcium in the granulation with no added alkalising or buffering substance is equivalent.

The pharmaceutical formulation, which is the object of the present invention, may contain, in addition to atorvastatin calcium, one or more fillers such as microcrystalline cellulose, lactose, sugars, starches, modified starch, mannitol, sorbitol and other polyols, dextrin, dextran and maltodextran, calcium carbonate, calcium phosphate and/or hydrogen phosphate, sulfate, one or more binders such as lactose, starches, modified starch, dextrin, dextran and maltodextrin, microcrystalline cellulose, sugars, polyethylene glycols, hydroxypropyl methylcellulose, ethylcellulose, hydroxyethyl cellulose, methylcellulose, carboxy methylcellulose, sodium carboxy methylcellulose, gelatin, acacia gum, tragacanth, polyvinylpyrrolidone, magnesium aluminum silicate, one or more disintegrating agents such as cross-linked sodium carboxy methylcellulose, cross-linked polyvinylpyrrolidone, cross-linked carboxymethyl starch, starches and microcrystalline cellulose, magnesium aluminum silicate, polyacrylin potassium, one or more different glidants such as magnesium, calcium and zinc stearate, calcium behenate, sodium stearyl fumarate, talc, magnesium trisilicate, stearic acid, palmitic acid, carnauba wax, silicon dioxide, one or more buffering substances such as sodium citrate, dibasic sodium phosphate, calcium carbonate, hydrogen phosphate, phosphate, sulfate, magnesium carbonate, potassium citrate, potassium sorbate, sodium ascorbate, benzoate, hydrogen carbonate, hydrogen phosphate, or one or more basic substances such as MgO, MgOH, NaOH, Ca(OH)₂, tromethamine, Al Mg silicate, lauryl sulfate. If required, the formulation may also include surfactants and other conventional ingredients for solid pharmaceutical formulations such as coloring agents, lakes, flavoring agents and adsorbents. As surfactants the following may be used: ionic surfactants such as sodium lauryl sulfate or

non-ionic surfactants such as different poloxamers (polyoxyethylene and polyoxypropylene copolymers), natural or synthesized lecithins, esters of sorbitan and fatty acids (such as Span[®] (Atlas Chemie)), esters of
5 polyoxyethylenesorbitan and fatty acids (such as Tween[®] (Atlas Chemie)), polyoxyethylated hydrogenated castor oil (such as Cremophor[®] (BASF)), polyoxyethylene stearates (such as Myrj[®] (Atlas Chemie)) or cationic surfactants such as cetyl pyridine chloride or any combination of the herein abovementioned
10 surfactants.

The pharmaceutical formulations of the present invention may be provided either as solid pharmaceutical formulations, such as powders, granules, tablets, or capsules, for example, or as liquid pharmaceutical formulations, preferably filled in
15 capsules.

The solid pharmaceutical formulations according to the present invention, may be prepared as described below:

- The mixture of the active ingredient, a filler, a binder, an alkalising or buffering substance, a disintegrating agent
20 and if required a surfactant and other conventional ingredients for solid pharmaceutical formulations is homogenized employing suitable mixers, the mixture is compacted using suitable compaction machines or slugged on slugging machines, the compacts or slugs are triturated
25 and/or sieved, fillers, disintegrating agents, buffering substances, glidants, lubricants and other conventional inactive ingredients for tablets or capsules are added, and re-homogenized. The resulting mixture is compressed into tablets or filled into capsules.
- The mixture of the active ingredient, a filler, a binder, an alkalising or buffering substance, a disintegrating agent
30 and if required a surfactant and other conventional

ingredients for solid pharmaceutical formulations are homogenized employing suitable mixers, glidants and lubricants are added and re-homogenized. The resulting mixture is compressed into tablets or filled into capsules.

- 5 • The mixture of the active ingredient, a filler, a binder, an alkalising or buffering substance, a disintegrating agent and if required a surfactant and other conventional ingredients for solid pharmaceutical formulations are homogenized employing suitable mixers, granulated with a
- 10 suitable solvent such as water, ethanol, methanol, isopropyl alcohol, n-butyl alcohol, acetone, diethylether, ethylacetate, isopropyl acetate, methyl acetate, dichloromethane, chloroform, mixtures of these solvents such as ethanol and acetone, methanol and acetone,
- 15 dichloromethane and methanol, and the mixtures thereof. The resulting granulation is dried in suitable dryers such as standard tray dryers, fluidized bed dryers, vacuum and microwave dryers, at a temperature not exceeding 60°C. To the dried granulation, glidants, disintegrating agents,
- 20 alkalising or buffering substances, glidants and lubricants are added and if required other conventional ingredients for solid pharmaceutical formulations. The resulting mixture is re-homogenized and compressed into tablets or filled into capsules.

25 Optionally, tablets are film-coated.

The present invention is illustrated but in no way limited by the following examples.

EXAMPLESExamples 1-2

Tablets with added MgO or Na₂HPO₄

The ingredients, listed in the table below, were
 5 homogenized in a mixer and granulated with water and ethanol,
 respectively. The resulting granulation was dried in a vacuum
 dryer at a temperature not exceeding 60°C.

Composition	A3	A4
Atorvastatin amorphous, micronized*	20.00	20.00
Microcrystalline cellulose (Avicel PH112 or PH102)*	72.60	37.10
Lactose monohydrate (70-100 mesh)	34.80	20.00
Cross-linked carboxymethylcellulose (Ac-di-sol)	9.60	9.60
Polysorbate 80	1.30	1.30
Hydroxypropyl cellulose (Klucel EF)	2.00	2.00
MgO	26.00	-
Na ₂ HPO ₄	-	140.00
Demi water for granulation	70.00	-
Ethanol refined for granulation (96%)	-	50.00

*- Atorvastatin in the form of Ca salt in an equivalent amount,
 the difference is adjusted with an amount of microcrystalline
 10 cellulose

All quantities are given in milligrams (for one tablet). The
 quantity of the prepared granulation was sufficient for the
 preparation of 1000 units of 250 mg tablets.

To the dried granulation the following was added:

Microcrystalline cellulose (Avicel PH112)	71.90	48.20
Cross-linked carboxymethylcellulose (Ac-di-sol)	9.60	19.60
Aerosil 200	1.20	1.20
Mg stearate	1.00	1.00

15 The resulting mixture was re-homogenized and compressed
 into tablets. The pH values provided by one tablet in 900 ml of
 aqueous 0.001M HCl solution were the following:

	A3	A4
pH (1 tablet in 900 ml aqueous 0.001M HCl solution) after 15 min	6.09	6.06
pH (1 tablet in 900 ml aqueous 0.001M HCl solution) after 30 min	8.88	6.02

Examples 3-6

Capsules with amorphous and crystalline, respectively, atorvastatin calcium with added Tris and Na₃PO₄, respectively

- 5 The ingredients, listed in the table below, were homogenized in a mixer and granulated with water and ethanol, respectively. The resulting granulation was dried in a vacuum dryer at a temperature not exceeding 60°C.

Composition	AK1	AK2	AA1	AA2
Atorvastatin crystalline*	20.0	20.0	-	-
Atorvastatin amorphous*	-	-	20.0	20.0
Microcrystalline cellulose (PH102)*	71.3	71.3	71.3	71.3
Lactose monohydrate (70-100 mesh)	34.8	34.8	34.8	34.8
Cross-linked carboxymethylcellulose (Ac-di-sol)	9.6	9.6	9.6	9.6
Polysorbate 80	2.6	2.6	2.6	2.6
Hydroxypropyl cellulose (Klucel EF)	2.0	2.0	2.0	2.0
Tris	110.0	-	110.0	-
Na ₃ PO ₄	-	80.0	-	80.0
Demi water for granulation	80.0	80.0	80.0	80.0

- 10 All quantities required for preparation of the granulation for one capsules are given in milligrams. The quantity of the prepared granulation was sufficient for filling 1000 capsules.

To the dried granulation the following was added:

Microcrystalline cellulose (Avicel PH112)	67.9	67.9	67.9	67.9
Cross-linked carboxymethylcellulose (Ac-di-sol)	9.6	9.6	9.6	9.6
Aerosil 200	1.2	1.2	1.2	1.2
Mg stearate	1.0	1.0	1.0	1.0

- 15 The resulting mixture was re-homogenized and compressed into tablets. The pH values provided by one tablet in 900 ml of aqueous 0.001M HCl solution were the following:

	AK1	AK2	AA1	AA2
pH (1 tablet in 900 ml aqueous 0.001M HCl solution) after 15 min	6.68	6.28	5.81	6.28
pH (1 tablet in 900 ml aqueous 0.001M HCl solution) after 30 min	6.95	6.72	5.68	6.30

Optionally, used atorvastatin could be micronized or prepared according to some other method to enlarge a specific surface area of the particles (e.g., grinding)

Claims:

1. Atorvastatin calcium in a pharmaceutical form of an aqueous solution having a pH equal to or greater than the pK_a+1 of atorvastatin calcium.
- 5 2. A composition comprising atorvastatin calcium providing a pH equal to or greater than the pK_a+1 of atorvastatin calcium to an aqueous solution thereof.
3. The composition according to claim 2 comprising further a pH adjusting substance.
- 10 4. The composition according to claim 3 wherein the pH adjusting substance increases the pH of an aqueous solution equal to or greater than the pK_a+1 of atorvastatin calcium.
5. The composition according to any of the claims 2 to 4 wherein the pH is adjusted to 6 or more.
- 15 6. The composition according to any of the claims 2 to 5, wherein the pH adjusting substance is at least one substance selected from alkalising and buffering substances.
7. A pharmaceutical formulation comprising atorvastatin calcium as active ingredient,
- 20 **characterized in that**
the pharmaceutical formulation when dissolved in a liquid aqueous medium increases the pH of said medium to a pH equal to or greater than pK_a+1 of atorvastatin calcium.
8. The pharmaceutical formulation according to claim 7,
25 wherein the atorvastatin calcium is present in the formulation in different physical forms.

9. The pharmaceutical formulation according to claim 7 or 8, wherein the atorvastatin calcium is present in the formulation in a crystalline and/or amorphous form at the same time.
10. The pharmaceutical formulation according to any of the
5 claims 7 to 9, wherein the atorvastatin calcium comprises amorphous atorvastatin calcium having a large specific surface of the particles.
11. The pharmaceutical formulation according to claim 10,
10 wherein the atorvastatin calcium comprises micronized amorphous atorvastatin calcium.
12. The pharmaceutical formulation according to any of the claims 7 to 9, wherein the atorvastatin calcium comprises crystalline atorvastatin calcium.
13. The pharmaceutical formulation according to any of the
15 claims 7 to 12, wherein the formulation provides in the simulated gastric fluid of pH of 3 a pH of equal to or greater than pK_a+1 .
14. The pharmaceutical formulation according to claim 13, wherein the formulation provides a pH of 6.
- 20 15. The pharmaceutical formulation according to any of the claims 7 to 14, wherein the amount of the pH adjusting substance is adjusted in the formulation such that a single administration increases the pH of 900 ml aqueous HCl solution having a pH of about 3, in particular 900 ml of a 0.001 M HCl
25 solution, to a pH equal to or greater than pK_a+1 or more.
16. The pharmaceutical formulation according to any of the preceding claims, wherein the pH adjusting substance is contained in the pharmaceutical formulation in an amount of 0.2 to 2.0 mmol, in particular in an amount of 0.4 to 1.2 mmol.

17. The pharmaceutical formulation according to any of the claims 7 to 16, wherein the pH adjusting substance is selected from the group of metal oxides, inorganic bases, organic bases, and salts of organic and inorganic acids.

5 18. The pharmaceutical formulation according to any of the claims 7 to 17, wherein the pH adjusting substance is selected from the group consisting of metal oxides, oxides or hydroxides of the alkaline or alkaline earth metals, in particular MgO, alkaline phosphate buffers, in particular Na₃PO₄ and Na₂HPO₄, and
10 organic amines, in particular tris(hydroxymethyl)methylamine.

19. The pharmaceutical formulation according to any of the claims 7 to 18 in the form of a powder, granules, a tablet or a capsule.

20. The pharmaceutical formulation according to any of the
15 claims 7 to 19 comprising further one or more components selected from the group of fillers, binders, buffering substances, basic substances, surfactants and other pharmaceutically acceptable ingredients.

21. A process for the preparation of a pharmaceutical formulation
20 comprising atorvastatin calcium as active ingredient,

characterized by the following steps:

- (a) mixing the active ingredient with at least one component selected from the group consisting of alkalising and/or buffering substances, fillers, binders, disintegrants, and
25 surfactants;
- (b) homogenizing the above mixture;
- (c) adding additional ingredients to the above mixture;
- (d) re-homogenizing the resulting mixture; and
- (e) final processing the re-homogenized mixture in
30 administrable form.

22. The process according to claim 21 wherein the final processing step (e) is compressing the re-homogenized mixture into tablets.

23. The process according to claim 21 wherein the final
5 processing step (e) is filling the re-homogenized mixture into capsules.

24. The process according to any of the claims 21 to 23, further comprising the steps of:

- (f) compacting the mixture after homogenization; and
- 10 (g) further processing including tritulating and/or sieving the compacted mixture before adding additional ingredients.

25. The process according to any of the claims 21 to 24, further comprising the steps of:

- 15 (h) granulating the homogenisate obtained in step (b) with granulation liquid; and
- (i) drying the obtained granulate before adding additional ingredients.

26. The process according to claim 24 or 25, wherein the additional ingredients are selected from the group consisting
20 of fillers, binders, disintegrants, alkalising agents, and glidants.

27. The process according to any of the claims 21 to 26, wherein the addition of the pH adjusting substance is adjusted such that a single administration of the formulation increases
25 the pH of the acidic environment to a pH equal to or greater than pK_a+1 of atorvastatin calcium.

28. The process according to claim 27, wherein the addition of the pH adjusting substance is adjusted such that a single administration of the formulation increases the pH of the acidic environment to a pH of 5.5 or more.

5 29. The process according to any of the claims 21 to 28 for the preparation of a solid formulation according to any of the claims 7 to 20.

30. The use of a solid formulation according to any of the claims 7 to 20 or of a solid formulation prepared according to
10 any of the claims 21 to 29 for the treatment of hypercholesterolemia and hyperlipidemia.

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
19 September 2002 (19.09.2002)

PCT

(10) International Publication Number
WO 2002/072073 A3

- (51) International Patent Classification⁷: **A61K 9/16**, 9/20, 31/40, A61P 3/06
- (21) International Application Number: PCT/IB2002/000736
- (22) International Filing Date: 13 March 2002 (13.03.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: P-200100069 14 March 2001 (14.03.2001) SI
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): LEK PHARMACEUTICAL AND CHEMICAL COMPANY D.D. [SI/SI]; Legal Affairs and Industrial Property, Verovskova 57, 1526 Ljubljana (SI).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): KEREC, Janez [SI/SI]; Trebinjska 7, 1000 Ljubljana (SI). MATEJA, Salobir [SI/SI]; ul. 28. Maja 9, 1000 Ljubljana (SI). BAVEC, Sasa [SI/SI]; Mekinceva 15, 1000 Ljubljana (SI).
- Published:
— with international search report
- (88) Date of publication of the international search report: 13 May 2004
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 2002/072073 A3

(54) Title: PHARMACEUTICAL FORMULATION COMPRISING ATORVASTATIN CALCIUM

(57) Abstract: Atorvastatin calcium can exist in an amorphous form or in one of the at least four known crystalline forms (Form I, Form II, Form III and Form IV). Atorvastatin calcium is the substance which is sparingly soluble in water, with pKa 4,5, and it has been found that the crystalline forms are less soluble than the amorphous form, which may cause problems in bioavailability of atorvastatin in the body. The present invention solves the problem of providing therapeutic equivalence of atorvastatin pharmaceutical formulation regardless the form (crystalline, amorphous, mixture of both) of atorvastatin calcium used for its preparation.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 02/00736

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/16 A61K9/20 A61K31/40 A61P3/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 16693 A (WARNER LAMBERT CO) 4 August 1994 (1994-08-04) cited in the application page 4, line 30 -page 5, line 29 examples claims 1,2,8 ---	2-30
X	WO 00 35425 A (LEK TOVARNA FARMACEVTSKI) 22 June 2000 (2000-06-22) cited in the application page 3, line 10 -page 4, line 20 example 6 ---	2-30
Y	WO 97 03958 A (WARNER LAMBERT CO) 6 February 1997 (1997-02-06) cited in the application page 13, line 27 - line 36 example 3 ---	1
-/-		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

13 November 2002

Date of mailing of the international search report

21/11/2002

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Epskamp, S

INTERNATIONAL SEARCH REPORT

PCT/IB 02/00736

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 03959 A (WARNER LAMBERT CO) 6 February 1997 (1997-02-06) cited in the application page 24, line 25 - line 34 examples	1
Y	--- KEARNEY AS ET AL: "The interconversion kinetics, equilibrium, and solubilities of the lactone and hydroxyacid forms of the HMG-CoA reductase inhibitor, CI-981." PHARMACEUTICAL RESEARCH (NEW YORK), vol. 10, no. 10, 1993, pages 1461-1465, XP008010404 ISSN: 0724-8741 abstract figure 2	1
A	--- WO 97 03960 A (WARNER LAMBERT CO) 6 February 1997 (1997-02-06) cited in the application example 2	
P,X	--- WO 01 76566 A (TEVA PHARMACEUTICAL IND) 18 October 2001 (2001-10-18) examples 5,8 -----	1-30

INTERNATIONAL SEARCH REPORT

PCT/IB 02/00736

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9416693	A	04-08-1994	AT 178794 T 15-04-1999
		CA 2150372 A1 04-08-1994	
		DE 69324504 D1 20-05-1999	
		DE 69324504 T2 26-08-1999	
		DK 680320 T3 25-10-1999	
		EP 0680320 A1 08-11-1995	
		ES 2133158 T3 01-09-1999	
		GR 3030359 T3 30-09-1999	
		JP 3254219 B2 04-02-2002	
		JP 8505640 T 18-06-1996	
		MX 9400281 A1 29-07-1994	
		SG 45369 A1 16-10-1998	
		WO 9416693 A1 04-08-1994	
		US 5686104 A 11-11-1997	
		US 6126971 A 03-10-2000	
WO 0035425	A	22-06-2000	SI 20109 A 30-06-2000
		AU 6360899 A 03-07-2000	
		BG 105559 A 31-12-2001	
		CN 1330538 T 09-01-2002	
		CZ 20011727 A3 12-09-2001	
		EP 1148872 A1 31-10-2001	
		HR 20010325 A1 30-06-2002	
		HU 0104258 A2 28-03-2002	
		WO 0035425 A1 22-06-2000	
		JP 2002532409 T 02-10-2002	
		PL 347686 A1 22-04-2002	
		SK 8092001 A3 08-10-2001	
		TR 200101235 T2 22-10-2001	
WO 9703958	A	06-02-1997	AT 207465 T 15-11-2001
		AU 725368 B2 12-10-2000	
		AU 6484196 A 18-02-1997	
		BG 63629 B1 31-07-2002	
		BG 102186 A 30-10-1998	
		BR 9610567 A 06-07-1999	
		CA 2220458 A1 06-02-1997	
		CN 1190957 A ,B 19-08-1998	
		CZ 9800123 A3 17-06-1998	
		DE 69616358 D1 29-11-2001	
		DK 848704 T3 04-02-2002	
		EE 9800016 A 17-08-1998	
		EP 0848704 A1 24-06-1998	
		ES 2166456 T3 16-04-2002	
		HR 960313 A1 30-04-1998	
		HU 9901687 A2 28-10-1999	
		IL 122162 A 14-07-1999	
		JP 11509229 T 17-08-1999	
		JP 3296563 B2 02-07-2002	
		NO 980208 A 16-01-1998	
		NZ 312906 A 22-12-2000	
		PL 324532 A1 08-06-1998	
		SK 5998 A3 06-05-1998	
		TW 401399 B 11-08-2000	
		WO 9703958 A1 06-02-1997	
		US 6121461 A 19-09-2000	
WO 9703959	A	06-02-1997	AT 208375 T 15-11-2001

INTERNATIONAL SEARCH REPORT

PCT/IB 02/00736

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO 9703959	A	AU 725424 B2	12-10-2000	
		AU 6484296 A	18-02-1997	
		BG 63630 B1	31-07-2002	
		BG 102187 A	30-10-1998	
		BR 9609872 A	23-03-1999	
		CA 2220018 A1	06-02-1997	
		CN 1190955 A ,B	19-08-1998	
		CZ 9800121 A3	14-10-1998	
		DE 69616808 D1	13-12-2001	
		DE 69616808 T2	29-05-2002	
		DK 848705 T3	04-02-2002	
		EE 9800015 A	17-08-1998	
		EP 1148049 A1	24-10-2001	
		EP 0848705 A1	24-06-1998	
		ES 2167587 T3	16-05-2002	
		HR 960339 A1	30-04-1998	
		HU 9900678 A2	28-07-1999	
		IL 122118 A	14-07-1999	
		JP 11509230 T	17-08-1999	
		JP 3296564 B2	02-07-2002	
		NO 980207 A	16-01-1998	
		NZ 312907 A	22-12-2000	
		PL 324496 A1	25-05-1998	
		PT 848705 T	28-02-2002	
		SI 848705 T1	30-04-2002	
		SK 6298 A3	07-10-1998	
		WO 9703959 A1	06-02-1997	
		US 5969156 A	19-10-1999	

WO 9703960	A	06-02-1997	AT 199542 T	15-03-2001
		AU 700794 B2	14-01-1999	
		AU 6497896 A	18-02-1997	
		BG 63631 B1	31-07-2002	
		BG 102188 A	31-08-1998	
		BR 9609714 A	23-02-1999	
		CA 2220455 A1	06-02-1997	
		CN 1190956 A ,B	19-08-1998	
		CZ 9800122 A3	16-12-1998	
		DE 69611999 D1	12-04-2001	
		DE 69611999 T2	26-07-2001	
		DK 839132 T3	09-04-2001	
		EE 9700369 A	15-06-1998	
		EP 0839132 A1	06-05-1998	
		ES 2156997 T3	01-08-2001	
		GR 3035859 T3	31-08-2001	
		HR 960312 A1	28-02-1998	
		HU 220343 B	28-12-2001	
		IL 122161 A	14-07-1999	
		JP 11510486 T	14-09-1999	
		NO 980209 A	16-01-1998	
		NZ 313008 A	28-01-2000	
		PL 324463 A1	25-05-1998	
		PT 839132 T	29-06-2001	
		SI 839132 T1	30-06-2001	
		SK 5898 A3	05-08-1998	
		WO 9703960 A1	06-02-1997	
		US 6274740 B1	14-08-2001	

INTERNATIONAL SEARCH REPORT

PCT/IB 02/00736

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0176566 A	18-10-2001	AU 5328701 A	23-10-2001
		WO 0176566 A1	18-10-2001
		US 2002035142 A1	21-03-2002

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 02/00736

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 30 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.